echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fosun Pharma Holding Subsidiary Cycloserine Capsule Drug Registration Application Accepted

    Fosun Pharma Holding Subsidiary Cycloserine Capsule Drug Registration Application Accepted

    • Last Update: 2022-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 14, Fosun Pharma announced that the cycloserine capsules independently developed by its holding subsidiary, Hongqi Pharma, have been successfully used in the treatment of active pulmonary tuberculosis and extrapulmonary tuberculosis (including renal tuberculosis) for which first-line anti-tuberculosis drugs are not effective.


    As of the date of this announcement, the cycloserine capsules approved for listing in China (excluding Hong Kong, Macao and Taiwan, the same below) mainly include Celexin® from Zhejiang Hisun Pharmaceutical Co.


    As of January 2022, the Group has invested approximately RMB 10.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.